A Retrospective Cohort Study to Characterize Patient Characteristics and Treatment Outcomes Among Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Database (20190402)

Study identification

• EU PAS number:
  EUPAS40706
• Study ID:
  50487
• Official title and acronym:
  A Retrospective Cohort Study to Characterize Patient Characteristics and Treatment Outcomes Among Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Database (20190402)
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  A retrospective cohort study of locally advanced (stage IIIB/C) or metastatic (stage IIIB/C) non-small cell lung cancer (NSCLC) in the French Epidemiological Strategy and Medical Economics Advanced or Metastatic Lung Cancer (ESME-AMLC) Data Platform. ; The study population consists of adult (≥ 18 years of age) patients diagnosed with locally advanced or metastatic (stage IV) non squamous NSCLC between 1 Jan 2015 – 30 Jun 2022. ; Patients are followed up from the date of diagnosis of advanced or metastatic NSCLC until death or date of last contact whichever occurs first.
• Study status:
  Finalised

Research institutions and networks

Institutions

Unicancer

France

Study timelines

Date when funding contract was signed

Actual: 07/08/2020

Study start date

Planned: 15/09/2020

Actual: 15/09/2020

Data analysis start date

Planned: 15/12/2020

Actual: 15/12/2020

Date of final study report

Planned: 30/06/2024

Actual: 27/05/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable